Trial Profile
A Phase IIa, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Genotype 4 Infection.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2015
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms NIAID SYNERGY
- 31 Aug 2015 New trial record